How long does BuSpar withdrawal last?

BuSpar withdrawal typically begins 1-3 days after stopping, peaks around 3-7 days, and resolves within Typically within 1-2 weeks. Rebound anxiety may persist 2-4 weeks if the underlying anxiety condition is not addressed

What tips do others have for tapering BuSpar?

Buspirone is one of the easier psychiatric medications to come off — most members do not experience the kind of withdrawal SSRIs or benzos cause. Avoid grapefruit juice during your taper — it can spike levels and add unnecessary side effects. If your anxiety returns within 1-2 weeks of stopping, that is more likely the underlying condition re-emerging rather than withdrawal. Plan a non-pharmacological anxiety toolkit (CBT skills, exercise, sleep) before stopping — it pays off in the rebound period.

Forums/Drug Profiles/

BuSpar Tapering Guide

buspirone

OtherFDA 1986

Go to Community Forum

Overview

Buspirone is an azapirone anxiolytic approved for generalized anxiety disorder (GAD). Unlike benzodiazepines, it has no sedative, muscle-relaxant, or anticonvulsant properties and is not associated with dependence.

Common Doses

5mg, 7.5mg, 10mg, 15mg, 30mg (typically dosed BID-TID)

Formulations

Tablets: 5mg, 7.5mg, 10mg, 15mg, 30mg (most are scored for splitting)

Pregnancy

Category B (animal studies show no risk; human data limited)

Mechanism of Action

Partial agonist at presynaptic and postsynaptic 5-HT1A serotonin receptors. Weak dopamine D2 antagonist. Onset of anxiolytic effect is delayed (2-4 weeks).

Taper Notes

Buspirone has minimal classical withdrawal because it does not act on GABA. Most patients can discontinue with a 1-2 week stepdown. Rebound anxiety is the main concern.

Maudsley Deprescribing Guidance

Buspirone is not associated with the dependence or discontinuation syndrome seen with SSRIs or benzodiazepines. A short stepdown (e.g., halve dose for 1 week, then stop) is usually sufficient. Slower if used long-term or in combination with other anxiolytics.

Tapering Protocol

Evidence-based phased reduction schedule. Always taper under medical supervision.

Phase	Duration	Notes
Initial reduction	1 week	Halve total daily dose. Most patients tolerate this step well.
Final reduction	1 week	Reduce to lowest available dose, then stop. Watch for rebound anxiety.

Withdrawal Timeline

⏱Onset

1-3 days after stopping

📈Peak Severity

3-7 days

📉Resolution

Typically within 1-2 weeks

⚠️Protracted Risk

Rebound anxiety may persist 2-4 weeks if the underlying anxiety condition is not addressed

Community Tips

Practical insights shared by members tapering BuSpar. Not medical advice — always consult your prescriber.

1Buspirone is one of the easier psychiatric medications to come off — most members do not experience the kind of withdrawal SSRIs or benzos cause.
2Avoid grapefruit juice during your taper — it can spike levels and add unnecessary side effects.
3If your anxiety returns within 1-2 weeks of stopping, that is more likely the underlying condition re-emerging rather than withdrawal.
4Plan a non-pharmacological anxiety toolkit (CBT skills, exercise, sleep) before stopping — it pays off in the rebound period.

Common Withdrawal Symptoms

rebound anxietyirritabilitysleep disturbancerestlessness

Interactions & Safety

Drug Interactions

MAOIs — contraindicated (hypertensive crisis risk)
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) — markedly increased exposure
Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) — markedly reduced exposure

Food Interactions

Grapefruit juice substantially increases plasma levels via CYP3A4 inhibition — avoid
Take consistently with or without food to avoid dose-curve fluctuations

Contraindications

Concurrent or recent (within 14 days) MAOI use
Severe hepatic or renal impairment
Known hypersensitivity to buspirone

Toxicity

Generally low toxicity. Serotonin syndrome possible with serotonergic combinations. Dizziness, headache, nausea, and lightheadedness most common adverse effects.

Sources & References

BuSpar (buspirone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Regulatory sources

Official prescribing information and safety notices.

FDA prescribing information — BuSpar (buspirone)

Peer-reviewed research

Primary literature cited in this taper guide.

Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)

Clinical guidelines

Evidence-based deprescribing and prescribing standards.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.

Pharmacokinetics

ADME Profile

Absorption

Rapidly absorbed but extensive first-pass metabolism limits oral bioavailability to ~4%. Food increases bioavailability.

Distribution

~5.3 L/kg

Metabolism

Extensive hepatic metabolism via CYP3A4 to multiple metabolites including the active 1-(2-pyrimidinyl)-piperazine (1-PP).

Elimination

Renal (~29-63% as metabolites), fecal (~18-38%).

Protein Binding

~95%

Clearance

~28 mL/min/kg

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber